Cwm LLC Acquires 2,356 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cwm LLC lifted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 52.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,835 shares of the company’s stock after purchasing an additional 2,356 shares during the quarter. Cwm LLC’s holdings in Takeda Pharmaceutical were worth $97,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TAK. EverSource Wealth Advisors LLC lifted its position in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical in the second quarter valued at about $59,000. Blue Trust Inc. raised its holdings in Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after acquiring an additional 2,330 shares in the last quarter. GAMMA Investing LLC boosted its position in Takeda Pharmaceutical by 136.1% during the third quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock valued at $90,000 after purchasing an additional 3,629 shares during the last quarter. Finally, Ridgewood Investments LLC bought a new position in Takeda Pharmaceutical in the second quarter valued at approximately $89,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Down 1.7 %

NYSE:TAK opened at $13.57 on Friday. The firm has a market capitalization of $42.95 billion, a price-to-earnings ratio of 24.67, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The stock’s 50 day moving average price is $14.59 and its two-hundred day moving average price is $13.77.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The firm had revenue of $7.75 billion for the quarter. Equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.58 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.